A sharp rise in circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks in the years
following the cessation of routine use of poliovirus type 2-containing oral polio vaccine and …

Background Novel oral poliovirus vaccine type 2 (nOPV2) has been engineered to improve
the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of …

Continued investment in the development and application of mathematical models of
poliovirus transmission, economics, and risks leads to their use in support of polio endgame …

Background Novel oral polio vaccine type 2 (nOPV2) has been used to interrupt circulating
vaccine-derived poliovirus type 2 outbreaks following its WHO emergency use listing. This …

The Global Polio Eradication Initiative owes much of its success in vastly reducing wild
poliovirus transmission globally to the use of live-attenuated Sabin oral poliovirus vaccine …

Inactivated poliovirus vaccine (IPV), available since 1955, became the first vaccine to be
used to protect against poliomyelitis. While the immunogenicity of IPV to prevent paralytic …

Background The outbreaks of circulating Vaccine Derived Polio Viruses (cVDPVs) have
emerged as a major challenge for the final stage of polio eradication. In Yemen, an …

Novel oral polio vaccine type 2 (nOPV2) has been genetically engineered to reduce the
reversion events that can occur with Sabin oral polio vaccine (OPV) and result in loss of …